<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">32266056</PMID>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2045-3701</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Cell &amp; bioscience</Title>
          <ISOAbbreviation>Cell Biosci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours.</ArticleTitle>
        <Pagination>
          <StartPage>54</StartPage>
          <MedlinePgn>54</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">54</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13578-020-00416-0</ELocationID>
        <Abstract>
          <AbstractText>The PI3 K/AKT/mTOR signalling pathway plays an important role in the regulation of signal transduction and biological processes such as cell proliferation, apoptosis, metabolism and angiogenesis. Compared with those of other signalling pathways, the components of the PI3K/AKT/mTOR signalling pathway are complicated. The regulatory mechanisms and biological functions of the PI3K/AKT/mTOR signalling pathway are important in many human diseases, including ischaemic brain injury, neurodegenerative diseases, and tumours. PI3K/AKT/mTOR signalling pathway inhibitors include single-component and dual inhibitors. Numerous PI3K inhibitors have exhibited good results in preclinical studies, and some have been clinically tested in haematologic malignancies and solid tumours. In this review, we briefly summarize the results of research on the PI3K/AKT/mTOR pathway and discuss the structural composition, activation, communication processes, regulatory mechanisms and biological functions of the PI3K/AKT/mTOR signalling pathway in the pathogenesis of neurodegenerative diseases and tumours.</AbstractText>
          <CopyrightInformation>© The Author(s) 2020.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Fei</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>1Department of Microbiology and Immunology, Shanghai University of Medicine &amp; Health Sciences, 279 Zhouzhu Rd, Shanghai, 201318 China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Collaborative Innovation Center of Shanghai University of Medicine &amp; Health Sciences, Shanghai, 201318 China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Na</LastName>
            <ForeName>Lixin</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Collaborative Innovation Center of Shanghai University of Medicine &amp; Health Sciences, Shanghai, 201318 China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>3Department of Inspection and Quarantine, Shanghai University of Medicine &amp; Health Sciences, Shanghai, 201318 China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yanfei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>3Department of Inspection and Quarantine, Shanghai University of Medicine &amp; Health Sciences, Shanghai, 201318 China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Linjun</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>3Department of Inspection and Quarantine, Shanghai University of Medicine &amp; Health Sciences, Shanghai, 201318 China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D016441">Retracted Publication</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>04</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cell Biosci</MedlineTA>
        <NlmUniqueID>101561195</NlmUniqueID>
        <ISSNLinking>2045-3701</ISSNLinking>
      </MedlineJournalInfo>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="RetractionIn">
          <RefSource>Cell Biosci. 2021 Aug 6;11(1):157</RefSource>
          <PMID Version="1">34362455</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Ischaemic brain injury</Keyword>
        <Keyword MajorTopicYN="Y">Neurodegenerative diseases</Keyword>
        <Keyword MajorTopicYN="Y">PI3K/AKT/mTOR signalling pathway</Keyword>
        <Keyword MajorTopicYN="Y">Regulatory mechanism</Keyword>
        <Keyword MajorTopicYN="Y">Tumour</Keyword>
      </KeywordList>
      <CoiStatement>Competing interestsThe authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32266056</ArticleId>
        <ArticleId IdType="pmc">PMC7110906</ArticleId>
        <ArticleId IdType="doi">10.1186/s13578-020-00416-0</ArticleId>
        <ArticleId IdType="pii">416</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bilanges B, Posor Y, Vanhaesebroeck B. PI3K isoforms in cell signalling and vesicle trafficking. Nat Rev Mol Cell Biol. 2019;20:515–534. doi: 10.1038/s41580-019-0129-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41580-019-0129-z</ArticleId>
            <ArticleId IdType="pubmed">31110302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jafari M, Ghadami E, Dadkhah T, Akhavan-Niaki H. PI3k/AKT signaling pathway: erythropoiesis and beyond. J Cell Physiol. 2019;234:2373–2385. doi: 10.1002/jcp.27262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.27262</ArticleId>
            <ArticleId IdType="pubmed">30192008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Zhang X. The role of PI3K/AKT/FOXO signaling in psoriasis. Arch Dermatol Res. 2019;311:83–91. doi: 10.1007/s00403-018-1879-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00403-018-1879-8</ArticleId>
            <ArticleId IdType="pubmed">30483877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Q, Jiang W, Hou P. Emerging role of PI3K/AKT in tumor-related epigenetic regulation. Semin Cancer Biol. 2019;59:112–124. doi: 10.1016/j.semcancer.2019.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2019.04.001</ArticleId>
            <ArticleId IdType="pubmed">30951826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez-Alegria K, Flores-Leon M, Avila-Munoz E, Rodriguez-Corona N, Arias C. PI3K signaling in neurons: a central node for the control of multiple functions. Int J Mol Sci. 2018;19:E3725. doi: 10.3390/ijms19123725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19123725</ArticleId>
            <ArticleId IdType="pmc">PMC6321294</ArticleId>
            <ArticleId IdType="pubmed">30477115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Very N, Vercoutter-Edouart AS, Lefebvre T, Hardiville S, El Yazidi-Belkoura I. Cross-dysregulation of O-GlcNAcylation and PI3K/AKT/mTOR axis in human chronic diseases. Front Endocrinol (Lausanne) 2018;9:602. doi: 10.3389/fendo.2018.00602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fendo.2018.00602</ArticleId>
            <ArticleId IdType="pmc">PMC6189293</ArticleId>
            <ArticleId IdType="pubmed">30356686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nur Husna SM, Tan HT, Mohamud R, Dyhl-Polk A, Wong KK. Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review. Ther Adv Med Oncol. 2018;10:1758835918808509. doi: 10.1177/1758835918808509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1758835918808509</ArticleId>
            <ArticleId IdType="pmc">PMC6236629</ArticleId>
            <ArticleId IdType="pubmed">30542378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuda S, Ikeda Y, Murakami M, Nakagawa Y, Tsuji A, Kitagishi Y. Roles of PI3K/AKT/GSK3 pathway involved in psychiatric illnesses. Diseases. 2019;7:E22. doi: 10.3390/diseases7010022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/diseases7010022</ArticleId>
            <ArticleId IdType="pmc">PMC6473240</ArticleId>
            <ArticleId IdType="pubmed">30781836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14:1483–1496. doi: 10.7150/ijbs.27173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijbs.27173</ArticleId>
            <ArticleId IdType="pmc">PMC6158718</ArticleId>
            <ArticleId IdType="pubmed">30263000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li YJ, Li XF, Yang EH, Shi M. Reaserch advances on the role of PI3K/AKT signaling pathway and MiRNA in acute T-cell lymphocytic leukemia—review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019;27:1344–1347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31418405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rai SN, Dilnashin H, Birla H, Singh SS, Zahra W, Rathore AS, Singh BK, Singh SP. The Role of PI3K/Akt and ERK in neurodegenerative disorders. Neurotox Res. 2019;35:775–795. doi: 10.1007/s12640-019-0003-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12640-019-0003-y</ArticleId>
            <ArticleId IdType="pubmed">30707354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yudushkin I. Getting the Akt together: guiding intracellular Akt activity by PI3K. Biomolecules. 2019;9:E67. doi: 10.3390/biom9020067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biom9020067</ArticleId>
            <ArticleId IdType="pmc">PMC6406913</ArticleId>
            <ArticleId IdType="pubmed">30781447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai CY, Dai KY, Fang C, Wu JCC, Chan SHH. PTEN/FLJ10540/PI3K/Akt cascade in experimental brain stem death: a newfound role for a classical tumorigenic signaling pathway. Biochem Pharmacol. 2018;155:207–212. doi: 10.1016/j.bcp.2018.07.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2018.07.002</ArticleId>
            <ArticleId IdType="pubmed">30008438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Presti D, Quaquarini E. The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR +/HER2- Metastatic Breast Cancer: Biological Mechanisms and New Treatments. Cancers (Basel) 2019;11:E1242. doi: 10.3390/cancers11091242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11091242</ArticleId>
            <ArticleId IdType="pmc">PMC6770492</ArticleId>
            <ArticleId IdType="pubmed">31450618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu X, Long YC, Shen HM. Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy. Autophagy. 2015;11:1711–1728. doi: 10.1080/15548627.2015.1043076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15548627.2015.1043076</ArticleId>
            <ArticleId IdType="pmc">PMC4824607</ArticleId>
            <ArticleId IdType="pubmed">26018563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gyori D, Chessa T, Hawkins PT, Stephens LR. Class (I) phosphoinositide 3-kinases in the tumor microenvironment. Cancers (Basel) 2017;9:E24. doi: 10.3390/cancers9030024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers9030024</ArticleId>
            <ArticleId IdType="pmc">PMC5366819</ArticleId>
            <ArticleId IdType="pubmed">28273837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghigo A, Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinases in health and disease. Subcell Biochem. 2012;58:183–213. doi: 10.1007/978-94-007-3012-0_6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-94-007-3012-0_6</ArticleId>
            <ArticleId IdType="pubmed">22403077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams R, Berndt A, Miller S, Hon WC, Zhang X. Form and flexibility in phosphoinositide 3-kinases. Biochem Soc Trans. 2009;37:615–626. doi: 10.1042/BST0370615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BST0370615</ArticleId>
            <ArticleId IdType="pubmed">19614567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome. 2002;13:169–172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11919689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brachmann SM, Ueki K, Engelman JA, Kahn RC, Cantley LC. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol Cell Biol. 2005;25:1596–1607. doi: 10.1128/MCB.25.5.1596-1607.2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.25.5.1596-1607.2005</ArticleId>
            <ArticleId IdType="pmc">PMC549361</ArticleId>
            <ArticleId IdType="pubmed">15713620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szymonowicz K, Oeck S, Malewicz NM, Jendrossek V. New insights into protein kinase B/Akt signaling: role of localized Akt activation and compartment-specific target proteins for the cellular radiation response. Cancers (Basel) 2018;10:E78. doi: 10.3390/cancers10030078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers10030078</ArticleId>
            <ArticleId IdType="pmc">PMC5876653</ArticleId>
            <ArticleId IdType="pubmed">29562639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Revathidevi S, Munirajan AK. Akt in cancer: mediator and more. Semin Cancer Biol. 2019;59:80–91. doi: 10.1016/j.semcancer.2019.06.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2019.06.002</ArticleId>
            <ArticleId IdType="pubmed">31173856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linton MF, Moslehi JJ, Babaev VR. Akt signaling in macrophage polarization, survival, and atherosclerosis. Int J Mol Sci. 2019;20:E2703. doi: 10.3390/ijms20112703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20112703</ArticleId>
            <ArticleId IdType="pmc">PMC6600269</ArticleId>
            <ArticleId IdType="pubmed">31159424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wadhwa B, Makhdoomi U, Vishwakarma R, Malik F. Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer. Anticancer Drugs. 2017;28:569–580. doi: 10.1097/CAD.0000000000000496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CAD.0000000000000496</ArticleId>
            <ArticleId IdType="pubmed">28379898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Risso G, Blaustein M, Pozzi B, Mammi P, Srebrow A. Akt/PKB: one kinase, many modifications. Biochem J. 2015;468:203–214. doi: 10.1042/BJ20150041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20150041</ArticleId>
            <ArticleId IdType="pubmed">25997832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simioni C, Martelli AM, Zauli G, Vitale M, McCubrey JA, Capitani S, Neri LM. Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: an update. J Cell Physiol. 2018;233:6440–6454. doi: 10.1002/jcp.26539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.26539</ArticleId>
            <ArticleId IdType="pubmed">29667769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tuncel G, Kalkan R. Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme. Med Oncol. 2018;35:122. doi: 10.1007/s12032-018-1185-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12032-018-1185-5</ArticleId>
            <ArticleId IdType="pubmed">30078108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu ST, Hui G, Mathis C, Chamie K, Pantuck AJ, Drakaki A. The current status and future role of the phosphoinositide 3 Kinase/AKT signaling pathway in urothelial cancer: an old pathway in the new immunotherapy era. Clin Genitourin Cancer. 2018;16:e269–e276. doi: 10.1016/j.clgc.2017.10.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clgc.2017.10.011</ArticleId>
            <ArticleId IdType="pubmed">29199023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar A, Rajendran V, Sethumadhavan R, Purohit R. AKT kinase pathway: a leading target in cancer research. Sci World J. 2013;2013:756134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3845396</ArticleId>
            <ArticleId IdType="pubmed">24327805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hollenhorst PC, Bose ME, Mielke MR, Muller U, Fox CA. Forkhead genes in transcriptional silencing, cell morphology and the cell cycle. Overlapping and distinct functions for FKH1 and FKH2 in Saccharomyces cerevisiae. Genetics. 2000;154:1533–1548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1461039</ArticleId>
            <ArticleId IdType="pubmed">10747051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xing YQ, Li A, Yang Y, Li XX, Zhang LN, Guo HC. The regulation of FOXO1 and its role in disease progression. Life Sci. 2018;193:124–131. doi: 10.1016/j.lfs.2017.11.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2017.11.030</ArticleId>
            <ArticleId IdType="pubmed">29158051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu M, Chen X, Chen D, Yu B, Huang Z. FoxO1: a novel insight into its molecular mechanisms in the regulation of skeletal muscle differentiation and fiber type specification. Oncotarget. 2017;8:10662–10674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5354690</ArticleId>
            <ArticleId IdType="pubmed">27793012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabrera-Ortega AA, Feinberg D, Liang Y, Rossa C, Jr, Graves DT. The role of forkhead box 1 (FOXO1) in the immune system: dendritic cells, T cells, B cells, and hematopoietic stem cells. Crit Rev Immunol. 2017;37:1–13. doi: 10.1615/CritRevImmunol.2017019636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1615/CritRevImmunol.2017019636</ArticleId>
            <ArticleId IdType="pmc">PMC6085137</ArticleId>
            <ArticleId IdType="pubmed">29431075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tia N, Singh AK, Pandey P, Azad CS, Chaudhary P, Gambhir IS. Role of forkhead box O (FOXO) transcription factor in aging and diseases. Gene. 2018;648:97–105. doi: 10.1016/j.gene.2018.01.051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2018.01.051</ArticleId>
            <ArticleId IdType="pubmed">29428128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Z, Xin Z, Hu W, Jiang S, Yang Z, Yan X, Li X, Yang Y, Chen F. Forkhead box O proteins: crucial regulators of cancer EMT. Semin Cancer Biol. 2018;50:21–31. doi: 10.1016/j.semcancer.2018.02.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2018.02.004</ArticleId>
            <ArticleId IdType="pubmed">29427645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiese K. Forkhead transcription factors: formulating a FOXO target for cognitive loss. Curr Neurovasc Res. 2017;14:415–420. doi: 10.2174/1567202614666171116102911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1567202614666171116102911</ArticleId>
            <ArticleId IdType="pmc">PMC5792363</ArticleId>
            <ArticleId IdType="pubmed">29149835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajendran NK, Dhilip Kumar SS, Houreld NN, Abrahamse H. Understanding the perspectives of forkhead transcription factors in delayed wound healing. J Cell Commun Signal. 2019;13:151–162. doi: 10.1007/s12079-018-0484-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12079-018-0484-0</ArticleId>
            <ArticleId IdType="pmc">PMC6498300</ArticleId>
            <ArticleId IdType="pubmed">30088222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gurnari C, Falconi G, De Bellis E, Voso MT, Fabiani E. The role of forkhead box proteins in acute myeloid leukemia. Cancers (Basel) 2019;11:E865. doi: 10.3390/cancers11060865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11060865</ArticleId>
            <ArticleId IdType="pmc">PMC6627614</ArticleId>
            <ArticleId IdType="pubmed">31234353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buteau J, Accili D. Regulation of pancreatic beta-cell function by the forkhead protein FoxO1. Diabetes Obes Metab. 2007;9(Suppl 2):140–146. doi: 10.1111/j.1463-1326.2007.00782.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1463-1326.2007.00782.x</ArticleId>
            <ArticleId IdType="pubmed">17919188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao X, Chen C, Guo P, Zhang T, Fischbach S, Fusco J, Shiota C, Prasadan K, Dong H, Gittes GK. Forkhead box protein 1 (FoxO1) inhibits accelerated beta cell aging in pancreas-specific SMAD7 mutant mice. J Biol Chem. 2017;292:3456–3465. doi: 10.1074/jbc.M116.770032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M116.770032</ArticleId>
            <ArticleId IdType="pmc">PMC5336177</ArticleId>
            <ArticleId IdType="pubmed">28057752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Shen L, Hong H, Li J, Wang H, Li X. Atrasentan alleviates high glucose-induced podocyte injury by the microRNA-21/forkhead box O1 axis. Eur J Pharmacol. 2019;852:142–150. doi: 10.1016/j.ejphar.2019.03.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2019.03.013</ArticleId>
            <ArticleId IdType="pubmed">30876973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Luo Y, Su Y, Teng L. The vitamin D receptor (VDR) protects pancreatic beta cells against forkhead box class O1 (FOXO1)-induced mitochondrial dysfunction and cell apoptosis. Biomed Pharmacother. 2019;117:109170. doi: 10.1016/j.biopha.2019.109170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biopha.2019.109170</ArticleId>
            <ArticleId IdType="pubmed">31261027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arioka M, Takahashi-Yanaga F. Glycogen synthase kinase-3 inhibitor as a multi-targeting anti-rheumatoid drug. Biochem Pharmacol. 2019;165:207–213. doi: 10.1016/j.bcp.2019.02.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2019.02.020</ArticleId>
            <ArticleId IdType="pubmed">30776323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandey MK, DeGrado TR. Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging. Theranostics. 2016;6:571–593. doi: 10.7150/thno.14334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.14334</ArticleId>
            <ArticleId IdType="pmc">PMC4775866</ArticleId>
            <ArticleId IdType="pubmed">26941849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, Klein PS. Glycogen synthase kinase-3 and alternative splicing. Wiley Interdiscip Rev RNA. 2018;9:e1501. doi: 10.1002/wrna.1501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/wrna.1501</ArticleId>
            <ArticleId IdType="pmc">PMC6185797</ArticleId>
            <ArticleId IdType="pubmed">30118183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golpich M, Amini E, Hemmati F, Ibrahim NM, Rahmani B, Mohamed Z, Raymond AA, Dargahi L, Ghasemi R, Ahmadiani A. Glycogen synthase kinase-3 beta (GSK-3beta) signaling: implications for Parkinson’s disease. Pharmacol Res. 2015;97:16–26. doi: 10.1016/j.phrs.2015.03.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2015.03.010</ArticleId>
            <ArticleId IdType="pubmed">25829335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer. 2010;9:144. doi: 10.1186/1476-4598-9-144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-9-144</ArticleId>
            <ArticleId IdType="pmc">PMC2906469</ArticleId>
            <ArticleId IdType="pubmed">20537194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dokken BB, Sloniger JA, Henriksen EJ. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle. Am J Physiol Endocrinol Metab. 2005;288:E1188–E1194. doi: 10.1152/ajpendo.00547.2004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpendo.00547.2004</ArticleId>
            <ArticleId IdType="pubmed">15671078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lochhead PA, Coghlan M, Rice SQ, Sutherland C. Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphatase and phosphoenolypyruvate carboxykinase gene expression. Diabetes. 2001;50:937–946. doi: 10.2337/diabetes.50.5.937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diabetes.50.5.937</ArticleId>
            <ArticleId IdType="pubmed">11334436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol. 2005;17:150–157. doi: 10.1016/j.ceb.2005.02.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ceb.2005.02.010</ArticleId>
            <ArticleId IdType="pubmed">15780591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han G, Casson RJ, Chidlow G, Wood JP. The mitochondrial complex I inhibitor rotenone induces endoplasmic reticulum stress and activation of GSK-3beta in cultured rat retinal cells. Invest Ophthalmol Vis Sci. 2014;55:5616–5628. doi: 10.1167/iovs.14-14371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1167/iovs.14-14371</ArticleId>
            <ArticleId IdType="pubmed">25082888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srinivasan S, Ohsugi M, Liu Z, Fatrai S, Bernal-Mizrachi E, Permutt MA. Endoplasmic reticulum stress-induced apoptosis is partly mediated by reduced insulin signaling through phosphatidylinositol 3-kinase/Akt and increased glycogen synthase kinase-3beta in mouse insulinoma cells. Diabetes. 2005;54:968–975. doi: 10.2337/diabetes.54.4.968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/diabetes.54.4.968</ArticleId>
            <ArticleId IdType="pubmed">15793234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma X, Zhou F, Chen Y, Zhang Y, Hou L, Cao X, Wang C. A polysaccharide from Grifola frondosa relieves insulin resistance of HepG2 cell by Akt-GSK-3 pathway. Glycoconj J. 2014;31:355–363. doi: 10.1007/s10719-014-9526-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10719-014-9526-x</ArticleId>
            <ArticleId IdType="pubmed">24908430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruvolo PP. GSK-3 as a novel prognostic indicator in leukemia. Adv Biol Regul. 2017;65:26–35. doi: 10.1016/j.jbior.2017.05.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbior.2017.05.001</ArticleId>
            <ArticleId IdType="pubmed">28499784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei X, Luo L, Chen J. Roles of mTOR signaling in tissue regeneration. Cells. 2019;8:E1075. doi: 10.3390/cells8091075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8091075</ArticleId>
            <ArticleId IdType="pmc">PMC6769890</ArticleId>
            <ArticleId IdType="pubmed">31547370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murugan AK. mTOR: role in cancer, metastasis and drug resistance. Semin Cancer Biol. 2019;9:92–111. doi: 10.1016/j.semcancer.2019.07.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2019.07.003</ArticleId>
            <ArticleId IdType="pubmed">31408724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Guan KL. mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol. 2019;21:63–71. doi: 10.1038/s41556-018-0205-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-018-0205-1</ArticleId>
            <ArticleId IdType="pubmed">30602761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khan MA, Jain VK, Rizwanullah M, Ahmad J, Jain K. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discov Today. 2019;24:2181–2191. doi: 10.1016/j.drudis.2019.09.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drudis.2019.09.001</ArticleId>
            <ArticleId IdType="pubmed">31520748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jhanwar-Uniyal M, Wainwright JV, Mohan AL, Tobias ME, Murali R, Gandhi CD, Schmidt MH. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Adv Biol Regul. 2019;72:51–62. doi: 10.1016/j.jbior.2019.03.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbior.2019.03.003</ArticleId>
            <ArticleId IdType="pubmed">31010692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karimi Roshan M, Soltani A, Soleimani A, Rezaie Kahkhaie K, Afshari AR, Soukhtanloo M. Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process. Biochimie. 2019;165:229–234. doi: 10.1016/j.biochi.2019.08.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biochi.2019.08.003</ArticleId>
            <ArticleId IdType="pubmed">31401189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rivera-Calderon LG, Fonseca-Alves CE, Kobayashi PE, Carvalho M, Vasconcelos RO, Laufer-Amorim R. p-mTOR, p-4EBP-1 and eIF4E expression in canine prostatic carcinoma. Res Vet Sci. 2019;122:86–92. doi: 10.1016/j.rvsc.2018.11.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rvsc.2018.11.006</ArticleId>
            <ArticleId IdType="pubmed">30476726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahoney RE, Azpurua J, Eaton BA. Insulin signaling controls neurotransmission via the 4eBP-dependent modification of the exocytotic machinery. Elife. 2016;5:e16807. doi: 10.7554/eLife.16807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.16807</ArticleId>
            <ArticleId IdType="pmc">PMC5012858</ArticleId>
            <ArticleId IdType="pubmed">27525480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaguchi M, Ikeya S, Kozaki A. The activation mechanism of plant S6 kinase (S6K), a substrate of TOR kinase, is different from that of mammalian S6K. FEBS Lett. 2019 doi: 10.1002/1873-3468.13661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1873-3468.13661</ArticleId>
            <ArticleId IdType="pubmed">31705659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Na EJ, Nam HY, Park J, Chung MA, Woo HA, Kim HJ. PI3K-mTOR-S6K signaling mediates neuronal viability via collapsin response mediator protein-2 expression. Front Mol Neurosci. 2017;10:288. doi: 10.3389/fnmol.2017.00288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnmol.2017.00288</ArticleId>
            <ArticleId IdType="pmc">PMC5605571</ArticleId>
            <ArticleId IdType="pubmed">28966575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Zhang Y, Yu Y. Global phosphoproteomic analysis of insulin/Akt/mTORC1/S6K signaling in rat hepatocytes. J Proteome Res. 2017;16:2825–2835. doi: 10.1021/acs.jproteome.7b00140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jproteome.7b00140</ArticleId>
            <ArticleId IdType="pmc">PMC5557384</ArticleId>
            <ArticleId IdType="pubmed">28689409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cretella D, Digiacomo G, Giovannetti E, Cavazzoni A. PTEN alterations as a potential mechanism for tumor cell escape from PD-1/PD-L1 inhibition. Cancers (Basel) 2019;11:E1318. doi: 10.3390/cancers11091318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11091318</ArticleId>
            <ArticleId IdType="pmc">PMC6770107</ArticleId>
            <ArticleId IdType="pubmed">31500143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luongo F, Colonna F, Calapa F, Vitale S, Fiori ME, De Maria R. PTEN tumor-suppressor: the dam of stemness in cancer. Cancers (Basel) 2019;11:E1076. doi: 10.3390/cancers11081076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11081076</ArticleId>
            <ArticleId IdType="pmc">PMC6721423</ArticleId>
            <ArticleId IdType="pubmed">31366089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naderali E, Khaki AA, Rad JS, Ali-Hemmati A, Rahmati M, Charoudeh HN. Regulation and modulation of PTEN activity. Mol Biol Rep. 2018;45:2869–2881. doi: 10.1007/s11033-018-4321-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11033-018-4321-6</ArticleId>
            <ArticleId IdType="pubmed">30145641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem. 2001;70:247–279. doi: 10.1146/annurev.biochem.70.1.247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.biochem.70.1.247</ArticleId>
            <ArticleId IdType="pubmed">11395408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stiles BL, Kuralwalla-Martinez C, Guo W, Gregorian C, Wang Y, Tian J, Magnuson MA, Wu H. Selective deletion of Pten in pancreatic beta cells leads to increased islet mass and resistance to STZ-induced diabetes. Mol Cell Biol. 2006;26:2772–2781. doi: 10.1128/MCB.26.7.2772-2781.2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.26.7.2772-2781.2006</ArticleId>
            <ArticleId IdType="pmc">PMC1430339</ArticleId>
            <ArticleId IdType="pubmed">16537919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen KT, Tajmir P, Lin CH, Liadis N, Zhu XD, Eweida M, Tolasa-Karaman G, Cai F, Wang R, Kitamura T, Belsham DD, Wheeler MB, Suzuki A, Mak TW, Woo M. Essential role of Pten in body size determination and pancreatic beta-cell homeostasis in vivo. Mol Cell Biol. 2006;26:4511–4518. doi: 10.1128/MCB.00238-06.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.00238-06</ArticleId>
            <ArticleId IdType="pmc">PMC1489140</ArticleId>
            <ArticleId IdType="pubmed">16738317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Md Mokhtar AH, Malik IA, Abd Aziz NAA, Almabhouh FA, Durairajanayagam D, Singh HJ. LY294002, a PI3K pathway inhibitor, prevents leptin-induced adverse effects on spermatozoa in Sprague-Dawley rats. Andrologia. 2019;51:e13196. doi: 10.1111/and.13196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/and.13196</ArticleId>
            <ArticleId IdType="pubmed">30456785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duarte A, Silveira GG, Soave DF, Costa JPO, Silva AR. The role of the LY294002—a non-selective inhibitor of phosphatidylinositol 3-kinase (PI3K) pathway—in cell survival and proliferation in cell line SCC-25. Asian Pac J Cancer Prev. 2019;20:3377–3383. doi: 10.31557/APJCP.2019.20.11.3377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.31557/APJCP.2019.20.11.3377</ArticleId>
            <ArticleId IdType="pmc">PMC7063005</ArticleId>
            <ArticleId IdType="pubmed">31759362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bavelloni A, Focaccia E, Piazzi M, Orsini A, Ramazzotti G, Cocco L, Blalock W, Faenza I. Therapeutic potential of nvp-bkm120 in human osteosarcomas cells. J Cell Physiol. 2019;234:10907–10917. doi: 10.1002/jcp.27911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.27911</ArticleId>
            <ArticleId IdType="pubmed">30536897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hainsworth JD, Becker KP, Mekhail T, Chowdhary SA, Eakle JF, Wright D, Langdon RM, Yost KJ, Padula GDA, West-Osterfield K, Scarberry M, Shaifer CA, Shastry M, Burris HA, 3rd, Shih K. Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II) J Neurooncol. 2019;144:303–311. doi: 10.1007/s11060-019-03227-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-019-03227-7</ArticleId>
            <ArticleId IdType="pubmed">31392595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinberg MA. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes. Anticancer Drugs. 2016;27:475–487. doi: 10.1097/CAD.0000000000000354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CAD.0000000000000354</ArticleId>
            <ArticleId IdType="pmc">PMC4881730</ArticleId>
            <ArticleId IdType="pubmed">26918392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaley TJ, Panageas KS, Mellinghoff IK, Nolan C, Gavrilovic IT, DeAngelis LM, Abrey LE, Holland EC, Lassman AB. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. J Neurooncol. 2019;144:403–407. doi: 10.1007/s11060-019-03243-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-019-03243-7</ArticleId>
            <ArticleId IdType="pmc">PMC7493746</ArticleId>
            <ArticleId IdType="pubmed">31325145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng K, Fan X, Li Q, Wang Y, Chen X, Xiao P, Passerini AG, Simon SI, Sun C. IRF-1 mediates the suppressive effects of mTOR inhibition on arterial endothelium. J Mol Cell Cardiol. 2020 doi: 10.1016/j.yjmcc.2020.02.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yjmcc.2020.02.006</ArticleId>
            <ArticleId IdType="pmc">PMC7138750</ArticleId>
            <ArticleId IdType="pubmed">32087218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendez-Gomez M, Castro-Mercado E, Pena-Uribe CA, Reyes-de la Cruz H, Lopez-Bucio J, Garcia-Pineda E. TARGET OF RAPAMYCIN signaling plays a role in Arabidopsis growth promotion by Azospirillum brasilense Sp245. Plant Sci. 2020;293:110416. doi: 10.1016/j.plantsci.2020.110416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.plantsci.2020.110416</ArticleId>
            <ArticleId IdType="pubmed">32081264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brakemeier S, Arns W, Lehner F, Witzke O, Vonend O, Sommerer C, Muhlfeld A, Rath T, Schuhmann R, Zukunft B, Kroeger I, Porstner M, Budde K. Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: results of a prospective randomized multicenter study (SENATOR) PLoS ONE. 2019;14:e0222730. doi: 10.1371/journal.pone.0222730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0222730</ArticleId>
            <ArticleId IdType="pmc">PMC6752944</ArticleId>
            <ArticleId IdType="pubmed">31536556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schotz U, Balzer V, Brandt FW, Ziemann F, Subtil FSB, Rieckmann T, Kocher S, Engenhart-Cabillic R, Dikomey E, Wittig A, Arenz A. Dual PI3K/mTOR inhibitor NVP-BEZ235 enhances radiosensitivity of head and neck squamous cell carcinoma (HNSCC) cell lines due to suppressed double-strand break (DSB) repair by non-homologous end joining. Cancers (Basel) 2020 doi: 10.3390/cancers12020467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers12020467</ArticleId>
            <ArticleId IdType="pmc">PMC7072694</ArticleId>
            <ArticleId IdType="pubmed">32085396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martins AC, Jr, Morcillo P, Ijomone OM, Venkataramani V, Harrison FE, Lee E, Bowman AB, Aschner M. New insights on the role of manganese in Alzheimer’s Disease and Parkinson’s Disease. Int J Environ Res Public Health. 2019;16:E3546. doi: 10.3390/ijerph16193546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijerph16193546</ArticleId>
            <ArticleId IdType="pmc">PMC6801377</ArticleId>
            <ArticleId IdType="pubmed">31546716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Affoo RH, Foley N, Rosenbek J, Shoemaker JK, Martin RE. Swallowing dysfunction and autonomic nervous system dysfunction in Alzheimer’s disease: a scoping review of the evidence. J Am Geriatr Soc. 2013;61:2203–2213. doi: 10.1111/jgs.12553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jgs.12553</ArticleId>
            <ArticleId IdType="pubmed">24329892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caricasole A, Copani A, Caruso A, Caraci F, Iacovelli L, Sortino MA, Terstappen GC, Nicoletti F. The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer’s disease? Trends Pharmacol Sci. 2003;24:233–238. doi: 10.1016/S0165-6147(03)00100-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-6147(03)00100-7</ArticleId>
            <ArticleId IdType="pubmed">12767722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howes AL, Arthur JF, Zhang T, Miyamoto S, Adams JW, Dorn GW, 2nd, Woodcock EA, Brown JH. Akt-mediated cardiomyocyte survival pathways are compromised by G alpha q-induced phosphoinositide 4,5-bisphosphate depletion. J Biol Chem. 2003;278:40343–40351. doi: 10.1074/jbc.M305964200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M305964200</ArticleId>
            <ArticleId IdType="pubmed">12900409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ksiezak-Reding H, Pyo HK, Feinstein B, Pasinetti GM. Akt/PKB kinase phosphorylates separately Thr212 and Ser214 of tau protein in vitro. Biochim Biophys Acta. 2003;1639:159–168. doi: 10.1016/j.bbadis.2003.09.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2003.09.001</ArticleId>
            <ArticleId IdType="pubmed">14636947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CW, Lau KF, Miller CC, Shaw PC. Glycogen synthase kinase-3 beta-mediated tau phosphorylation in cultured cell lines. NeuroReport. 2003;14:257–260. doi: 10.1097/00001756-200302100-00020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00001756-200302100-00020</ArticleId>
            <ArticleId IdType="pubmed">12598741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen Y, Planel E, Herman M, Figueroa HY, Wang L, Liu L, Lau LF, Yu WH, Duff KE. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci. 2008;28:2624–2632. doi: 10.1523/JNEUROSCI.5245-07.2008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.5245-07.2008</ArticleId>
            <ArticleId IdType="pmc">PMC6671193</ArticleId>
            <ArticleId IdType="pubmed">18322105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Do TD, Economou NJ, Chamas A, Buratto SK, Shea JE, Bowers MT. Interactions between amyloid-beta and Tau fragments promote aberrant aggregates: implications for amyloid toxicity. J Phys Chem B. 2014;118:11220–11230. doi: 10.1021/jp506258g.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jp506258g</ArticleId>
            <ArticleId IdType="pmc">PMC4174992</ArticleId>
            <ArticleId IdType="pubmed">25153942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitagishi Y, Nakanishi A, Ogura Y, Matsuda S. Dietary regulation of PI3K/AKT/GSK-3beta pathway in Alzheimer’s disease. Alzheimers Res Ther. 2014;6:35. doi: 10.1186/alzrt265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/alzrt265</ArticleId>
            <ArticleId IdType="pmc">PMC4075129</ArticleId>
            <ArticleId IdType="pubmed">25031641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrarini C, Russo M, Dono F, Di Pietro M, Rispoli MG, Di Stefano V, Ferri L, Barbone F, Vitale M, Thomas A, Sensi SL, Onofrj M, Bonanni L. A stage-based approach to therapy in Parkinson’s Disease. Biomolecules. 2019 doi: 10.3390/biom9080388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biom9080388</ArticleId>
            <ArticleId IdType="pmc">PMC6723065</ArticleId>
            <ArticleId IdType="pubmed">31434341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo S, Kang SS, Wang ZH, Liu X, Day JX, Wu Z, Peng J, Xiang D, Springer W, Ye K. Akt phosphorylates NQO1 and triggers its degradation, abolishing its antioxidative activities in Parkinson’s Disease. J Neurosci. 2019;39:7291–7305. doi: 10.1523/JNEUROSCI.0625-19.2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0625-19.2019</ArticleId>
            <ArticleId IdType="pmc">PMC6759025</ArticleId>
            <ArticleId IdType="pubmed">31358653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leikas JV, Kohtala S, Theilmann W, Jalkanen AJ, Forsberg MM, Rantamaki T. Brief isoflurane anesthesia regulates striatal AKT-GSK3beta signaling and ameliorates motor deficits in a rat model of early-stage Parkinson’s disease. J Neurochem. 2017;142:456–463. doi: 10.1111/jnc.14066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.14066</ArticleId>
            <ArticleId IdType="pmc">PMC5575520</ArticleId>
            <ArticleId IdType="pubmed">28488766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia Y, Mo SJ, Feng QQ, Zhan ML, OuYang LS, Chen JC, Ma YX, Wu JJ, Lei WL. EPO-dependent activation of PI3K/Akt/FoxO3a signalling mediates neuroprotection in in vitro and in vivo models of Parkinson’s disease. J Mol Neurosci. 2014;53:117–124. doi: 10.1007/s12031-013-0208-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12031-013-0208-0</ArticleId>
            <ArticleId IdType="pubmed">24390959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, Wang H, Liu L, Xie A. The role of insulin/IGF-1/PI3K/Akt/GSK3beta signaling in Parkinson’s disease dementia. Front Neurosci. 2018;12:73. doi: 10.3389/fnins.2018.00073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2018.00073</ArticleId>
            <ArticleId IdType="pmc">PMC5826217</ArticleId>
            <ArticleId IdType="pubmed">29515352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang W, He H, Song H, Zhao J, Li T, Wu L, Zhang X, Chen J. Neuroprotective effects of salidroside in the MPTP mouse model of Parkinson’s disease: involvement of the PI3K/Akt/GSK3beta pathway. Parkinsons Dis. 2016;2016:9450137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5050371</ArticleId>
            <ArticleId IdType="pubmed">27738547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong J, Zhang L, Zhang Q, Li X, Xia XJ, Liu YY, Yang QS. Lentiviral vector-mediated SHC3 silencing exacerbates oxidative stress injury in nigral dopamine neurons by regulating the PI3K-AKT-FoxO signaling pathway in rats with Parkinson’s disease. Cell Physiol Biochem. 2018;49:971–984. doi: 10.1159/000493228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000493228</ArticleId>
            <ArticleId IdType="pubmed">30184529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giacoppo S, Bramanti P, Mazzon E. Triggering of inflammasome by impaired autophagy in response to acute experimental Parkinson’s disease: involvement of the PI3K/Akt/mTOR pathway. NeuroReport. 2017;28:996–1007. doi: 10.1097/WNR.0000000000000871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WNR.0000000000000871</ArticleId>
            <ArticleId IdType="pmc">PMC5610561</ArticleId>
            <ArticleId IdType="pubmed">28902711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen WF, Wu L, Du ZR, Chen L, Xu AL, Chen XH, Teng JJ, Wong MS. Neuroprotective properties of icariin in MPTP-induced mouse model of Parkinson’s disease: involvement of PI3K/Akt and MEK/ERK signaling pathways. Phytomedicine. 2017;25:93–99. doi: 10.1016/j.phymed.2016.12.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phymed.2016.12.017</ArticleId>
            <ArticleId IdType="pubmed">28190476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribeiro M, Rosenstock TR, Oliveira AM, Oliveira CR, Rego AC. Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington’s disease knock-in striatal cells. Free Radic Biol Med. 2014;74:129–144. doi: 10.1016/j.freeradbiomed.2014.06.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2014.06.023</ArticleId>
            <ArticleId IdType="pubmed">24992836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaillant AR, Mazzoni I, Tudan C, Boudreau M, Kaplan DR, Miller FD. Depolarization and neurotrophins converge on the phosphatidylinositol 3-kinase-Akt pathway to synergistically regulate neuronal survival. J Cell Biol. 1999;146:955–966. doi: 10.1083/jcb.146.5.955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.146.5.955</ArticleId>
            <ArticleId IdType="pmc">PMC2169479</ArticleId>
            <ArticleId IdType="pubmed">10477751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silva A, Naia L, Dominguez A, Ribeiro M, Rodrigues J, Vieira OV, Lessmann V, Rego AC. Overexpression of BDNF and full-length TrkB receptor ameliorate striatal neural survival in Huntington’s disease. Neurodegener Dis. 2015;15:207–218. doi: 10.1159/000375447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000375447</ArticleId>
            <ArticleId IdType="pubmed">25896770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJ, Ferrer I, Rozemuller AJ, Hernandez F, Avila J, Lucas JJ. Huntington’s disease is a four-repeat tauopathy with tau nuclear rods. Nat Med. 2014;20:881–885. doi: 10.1038/nm.3617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3617</ArticleId>
            <ArticleId IdType="pubmed">25038828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>L’Episcopo F, Drouin-Ouellet J, Tirolo C, Pulvirenti A, Giugno R, Testa N, Caniglia S, Serapide MF, Cisbani G, Barker RA, Cicchetti F, Marchetti B. GSK-3beta-induced Tau pathology drives hippocampal neuronal cell death in Huntington’s disease: involvement of astrocyte-neuron interactions. Cell Death Dis. 2016;7:e2206. doi: 10.1038/cddis.2016.104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2016.104</ArticleId>
            <ArticleId IdType="pmc">PMC4855649</ArticleId>
            <ArticleId IdType="pubmed">27124580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riquelme I, Tapia O, Espinoza JA, Leal P, Buchegger K, Sandoval A, Bizama C, Araya JC, Peek RM, Roa JC. The gene expression status of the PI3K/AKT/mTOR pathway in gastric cancer tissues and cell lines. Pathol Oncol Res. 2016;22:797–805. doi: 10.1007/s12253-016-0066-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12253-016-0066-5</ArticleId>
            <ArticleId IdType="pmc">PMC5890336</ArticleId>
            <ArticleId IdType="pubmed">27156070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng TC, Din ZH, Su JH, Wu YJ, Liu CI. Sinulariolide suppresses cell migration and invasion by inhibiting matrix metalloproteinase-2/-9 and urokinase through the PI3K/AKT/mTOR signaling pathway in human bladder cancer cells. Mar Drugs. 2017 doi: 10.3390/md15080238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/md15080238</ArticleId>
            <ArticleId IdType="pmc">PMC5577593</ArticleId>
            <ArticleId IdType="pubmed">28767067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Li S, Li J, Wang D, Li Q. Effect of microRNA-135a on cell proliferation, migration, invasion, apoptosis and tumor angiogenesis through the IGF-1/PI3K/Akt signaling pathway in non-small cell lung cancer. Cell Physiol Biochem. 2017;42:1431–1446. doi: 10.1159/000479207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000479207</ArticleId>
            <ArticleId IdType="pubmed">28715819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang CZ, Wu SC, Chang CM, Lin CL, Kwan AL. Arctigenin, a potent ingredient of Arctium lappa L., induces endothelial nitric oxide synthase and attenuates subarachnoid hemorrhage-induced vasospasm through PI3K/Akt pathway in a rat model. Biomed Res Int. 2015;2015:490209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4619842</ArticleId>
            <ArticleId IdType="pubmed">26539501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsubaki M, Takeda T, Tomonari Y, Koumoto YI, Imano M, Satou T, Nishida S. Overexpression of HIF-1alpha contributes to melphalan resistance in multiple myeloma cells by activation of ERK1/2, Akt, and NF-kappaB. Lab Invest. 2019;99:72–84. doi: 10.1038/s41374-018-0114-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41374-018-0114-8</ArticleId>
            <ArticleId IdType="pubmed">30353128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patra K, Jana S, Sarkar A, Mandal DP, Bhattacharjee S. The inhibition of hypoxia-induced angiogenesis and metastasis by cinnamaldehyde is mediated by decreasing HIF-1alpha protein synthesis via PI3K/Akt pathway. BioFactors. 2019;45:401–415. doi: 10.1002/biof.1499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/biof.1499</ArticleId>
            <ArticleId IdType="pubmed">30854715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Xu J, Dong Y, Huang B. Down-regulation of HIF-1alpha inhibits the proliferation, migration, and invasion of gastric cancer by inhibiting PI3K/AKT pathway and VEGF expression. Biosci Rep. 2018 doi: 10.1155/2015/490209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2015/490209</ArticleId>
            <ArticleId IdType="pmc">PMC6435555</ArticleId>
            <ArticleId IdType="pubmed">29899167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei Y, Hong H, Zhang X, Lai W, Wang Y, Chu K, Brown J, Hong G, Chen L. Salidroside inhibits inflammation through PI3K/Akt/HIF signaling after focal cerebral ischemia in rats. Inflammation. 2017;40:1297–1309. doi: 10.1007/s10753-017-0573-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10753-017-0573-x</ArticleId>
            <ArticleId IdType="pubmed">28478514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chin YR, Toker A. The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol Cell. 2010;38:333–344. doi: 10.1016/j.molcel.2010.02.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2010.02.031</ArticleId>
            <ArticleId IdType="pmc">PMC2872630</ArticleId>
            <ArticleId IdType="pubmed">20471940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castellino RC, Durden DL. Mechanisms of disease: the PI3K-Akt-PTEN signaling node—an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol. 2007;3:682–693. doi: 10.1038/ncpneuro0661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncpneuro0661</ArticleId>
            <ArticleId IdType="pubmed">18046441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abraham J. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies? Expert Rev Anticancer Ther. 2015;15:51–68. doi: 10.1586/14737140.2015.961429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14737140.2015.961429</ArticleId>
            <ArticleId IdType="pubmed">25306975</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
